Induced pluripotent amniotic mesenchymal stem cell therapy - Amniotics
Latest Information Update: 21 Jul 2021
Price :
$50 *
At a glance
- Originator Amniotics
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 16 Jul 2021 Induced pluripotent stem cell therapy - Amniotics is available for licensing as of 16 Jul 2021. https://www.amniotics.com/rd/pipeline/
- 16 Jul 2021 Early research in Unspecified in Sweden (unspecified route) prior to July 2021 (Amniotics pipeline, July 2021)